Streetbeat News

Regulatory

YYGH

YY Group Holdings Limited (NASDAQ:YYGH) has regained compliance with NASDAQ's Minimum Bid Price Rule by maintaining a stock price above $1.00 for over 12 consecutive business days. The stock has risen by over 70% from a low of $0.71 to a peak of $1.295, reflecting market confidence in the company's growth and business model.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:33 pm

PALI

Palisade Bio has received approval from Health Canada to begin a Phase 1 clinical study for its lead program, PALI-2108, aimed at treating ulcerative colitis. The study will explore single and multiple ascending doses and food effects. The global ulcerative colitis market is projected to reach $10 billion by 2028.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:31 pm

SPY

The USA Consumer Price Index (CPI) for September increased by 2.4% year-over-year, slightly above the estimated 2.3% but below the prior 2.5%. This indicates a moderate inflationary trend.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:31 pm

SPY

The USA Core CPI for September increased by 0.3% month-over-month, surpassing the estimated 0.2% and matching the prior month's increase. This indicates a higher-than-expected inflation rate.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:30 pm

SPY

The Core Consumer Price Index (CPI) for September increased by 3.3% year-over-year, surpassing the expected 3.2% and the prior 3.2%. This indicates a higher-than-anticipated inflation rate.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:30 pm

SPY

The USA Consumer Price Index (CPI) for September increased by 0.2% month-over-month, surpassing the estimated 0.1% and matching the prior month's increase. This indicates a slight rise in inflationary pressures.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:30 pm

XNCR

Xencor has presented preclinical data on XmAb942, a high-potency anti-TL1A antibody aimed at treating inflammatory bowel diseases. A Phase 1 study in healthy volunteers is scheduled to start in Q4 2024, with initial data expected in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:18 pm

CMND

Clearmind Medicine's shares rise following Institutional Review Board approval for a Phase I/IIa clinical trial in the U.S. targeting alcohol use disorder.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:15 pm

ACHV

Achieve Life Sciences has completed the enrollment of 479 participants in its ORCA-OL clinical trial and reported that the first Data Safety Monitoring Committee review found no safety concerns.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:14 pm

ALLR

Allarity Therapeutics has regained compliance with Nasdaq's minimum bid price requirement, maintaining a closing bid price of $1.00 or more for 20 consecutive trading days.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:13 pm